Targeting the neddylation pathway in cells as a potential therapeutic approach for diseases

DNA damage and S phase-dependent E2F1 stabilization requires the cIAP1 E3-ubiquitin ligase and is associated with K63-poly-ubiquitination on lysine 161/164 residues

(2017) Valérie Glorian et al.   Cell Death & Disease

MLN4924 neddylation inhibitor promotes cell death in paclitaxel‑resistant human lung adenocarcinoma cells

(2017) Qiang Xu et al.   Oncology Letters

MLN4924 (Pevonedistat), a protein neddylation inhibitor, suppresses proliferation and migration of human clear cell renal cell carcinoma

(2017) Shuai Tong et al.   Scientific Reports

Search for Inhibitors of the Ubiquitin–Proteasome System from Natural Sources for Cancer Therapy

(2016) Sachiko Tsukamoto   CHEMICAL & PHARMACEUTICAL BULLETIN

A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma

(2016) Shailender Bhatia et al.   INVESTIGATIONAL NEW DRUGS

Characterization of the mammalian family of DCN-type NEDD8 E3 ligases

(2016) Matthew J. Keuss et al.   JOURNAL OF CELL SCIENCE

The NEDD8-activating enzyme inhibitor MLN4924 induces G2 arrest and apoptosis in T-cell acute lymphoblastic leukemia

(2016) Kun Han et al.   Oncotarget

Dysregulation of Ubiquitin-Proteasome System in Neurodegenerative Diseases

(2016) Qiuyang Zheng et al.   Frontiers in Aging Neuroscience

Inactivation of the CRL4-CDT2-SET8/p21 ubiquitylation and degradation axis underlies the therapeutic efficacy of pevonedistat in melanoma

(2016) Mouadh Benamar et al.   EBioMedicine

Cullin 3 Ubiquitin Ligases in Cancer Biology: Functions and Therapeutic Implications

(2016) Hsin-Yi Chen et al.   Frontiers in Oncology

Targeting deubiquitinase activity with a novel small-molecule inhibitor as therapy for B-cell malignancies

(2015) L. F. Peterson et al.   BLOOD

Targeting cullin-RING ligases for cancer treatment: rationales, advances and therapeutic implications

(2015) Shuju Wu et al.   CYTOTECHNOLOGY

Stabilization of LKB1 and Akt by neddylation regulates energy metabolism in liver cancer

(2015) Lucía Barbier-Torres et al.   Oncotarget

Novel strategies to target the ubiquitin proteasome system in multiple myeloma

(2015) Susanne Lub et al.   Oncotarget

Chemogenomic Study of Carboplatin in Saccharomyces cerevisiae: Inhibition of the NEDDylation Process Overcomes Cellular Resistance Mediated by HuR and Cullin Proteins

(2015) Graziele Fonseca de Sousa et al.   PLoS One

Targeting Neddylation Pathways to Inactivate Cullin-RING Ligases for Anticancer Therapy

(2014) Yongchao Zhao et al.   ANTIOXIDANTS & REDOX SIGNALING

MLN4924, an NAE inhibitor, suppresses AKT and mTOR signaling via upregulation of REDD1 in human myeloma cells

(2014) Y. Gu et al.   BLOOD

The Nedd8-Activating Enzyme Inhibitor MLN4924 Thwarts Microenvironment-Driven NF- B Activation and Induces Apoptosis in Chronic Lymphocytic Leukemia B Cells

(2014) J. C. Godbersen et al.   CLINICAL CANCER RESEARCH

Overactivated Neddylation Pathway as a Therapeutic Target in Lung Cancer

(2014) Lihui Li et al.   JNCI-Journal of the National Cancer Institute

Inactivating UBE2M Impacts the DNA Damage Response and Genome Integrity Involving Multiple Cullin Ligases

(2014) Scott Cukras et al.   PLoS One

Inhibition of the MDM2 E3 Ligase Induces Apoptosis and Autophagy in Wild-Type and Mutant p53 Models of Multiple Myeloma, and Acts Synergistically with ABT-737

(2014) Dongmin Gu et al.   PLoS One

Targeting p53 for Novel Anticancer Therapy

(2014) Zhen Wang et al.   Translational Oncology

LKB1 and AMPK and the cancer-metabolism link - ten years after

(2013) D Hardie et al.   BMC BIOLOGY

New orally active proteasome inhibitors in multiple myeloma

(2013) Alessandro Allegra et al.   LEUKEMIA RESEARCH

Preclinical assessment of JNJ-26854165 (Serdemetan), a novel tryptamine compound with radiosensitizing activity in vitro and in tumor xenografts

(2011) Cyrus Chargari et al.   CANCER LETTERS

Inhibition of NEDD8-Activating Enzyme Induces Rereplication and Apoptosis in Human Tumor Cells Consistent with Deregulating CDT1 Turnover

(2011) M. A. Milhollen et al.   CANCER RESEARCH

An Allosteric Inhibitor of the Human Cdc34 Ubiquitin-Conjugating Enzyme

(2011) Derek F. Ceccarelli et al.   CELL

Roles of COP9 signalosome in cancer

(2011) Mong-Hong Lee et al.   CELL CYCLE

CRL4Cdt2

(2011) Tarek Abbas et al.   CELL CYCLE

Murine double minute 2 regulates Hu antigen R stability in human liver and colon cancer through NEDDylation

(2011) Nieves Embade et al.   HEPATOLOGY

The cullin protein family

(2011) Antonio Sarikas et al.   GENOME BIOLOGY

MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF- B-dependent lymphoma

(2010) M. A. Milhollen et al.   BLOOD

The ubiquitin-activating enzyme E1 as a therapeutic target for the treatment of leukemia and multiple myeloma

(2010) G. W. Xu et al.   BLOOD

NEDD8-Targeting Drug MLN4924 Elicits DNA Rereplication by Stabilizing Cdt1 in S Phase, Triggering Checkpoint Activation, Apoptosis, and Senescence in Cancer Cells

(2010) J. J. Lin et al.   CANCER RESEARCH

Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer

(2010) E. Kupperman et al.   CANCER RESEARCH

Substrate-Assisted Inhibition of Ubiquitin-like Protein-Activating Enzymes: The NEDD8 E1 Inhibitor MLN4924 Forms a NEDD8-AMP Mimetic In Situ

(2010) James E. Brownell et al.   MOLECULAR CELL

CRL4Cdt2 Regulates Cell Proliferation and Histone Gene Expression by Targeting PR-Set7/Set8 for Degradation

(2010) Tarek Abbas et al.   MOLECULAR CELL

Posttranscriptional regulation of cancer traits by HuR

(2010) Kotb Abdelmohsen et al.   Wiley Interdisciplinary Reviews-RNA

Bortezomib induces canonical nuclear factor- B activation in multiple myeloma cells

(2009) T. Hideshima et al.   BLOOD

Regulation of cullin-RING E3 ubiquitin-ligases by neddylation and dimerization

(2009) J. Merlet et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Targeting NEDD8-Activated Cullin-RING Ligases for the Treatment of Cancer

(2009) T. A. Soucy et al.   CLINICAL CANCER RESEARCH

E2-RING Expansion of the NEDD8 Cascade Confers Specificity to Cullin Modification

(2009) Danny T. Huang et al.   MOLECULAR CELL

An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer

(2009) Teresa A. Soucy et al.   NATURE

The human Dcn1-like protein DCNL3 promotes Cul3 neddylation at membranes

(2009) N. Meyer-Schaller et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Novel substrates and functions for the ubiquitin-like molecule NEDD8: Figure 1

(2008) Dimitris P. Xirodimas   BIOCHEMICAL SOCIETY TRANSACTIONS

Structural Insights into NEDD8 Activation of Cullin-RING Ligases: Conformational Control of Conjugation

(2008) David M. Duda et al.   CELL

Ribosomal proteins are targets for the NEDD8 pathway

(2008) Dimitris P Xirodimas et al.   EMBO REPORTS

Function and regulation of protein neddylation. ‘Protein Modifications: Beyond the Usual Suspects’ Review Series

(2008) Gwénaël Rabut et al.   EMBO REPORTS

Discovery of a Potent, Selective, and Orally Active Proteasome Inhibitor for the Treatment of Cancer

(2008) Bruce D. Dorsey et al.   JOURNAL OF MEDICINAL CHEMISTRY

Nitric oxide prodrug JS-K inhibits ubiquitin E1 and kills tumor cells retaining wild-type p53

(2008) J Kitagaki et al.   ONCOGENE

Cullin-RING ubiquitin ligases: global regulation and activation cycles

(2008) Dimple R Bosu et al.   Cell Division